The high heterogeneity in the analysis of all cancer types was not unexpected given the range of tumour types identified, different disease stages and treatment statuses of the patients and the different protocols used to measure GR expression (Table 1 and Table 2). This evidence concerns the gene NR3C1 and neoplasm.